A Cell paper describing ENVLPE/ENVLPE+, virus-like particles engineered with nucleocytosolic-shuttling Gag-PCP to recruit aptamer-tagged (pe)gRNAs and preferentially package fully assembled CRISPR RNPs. Csy4-mediated 3' protection of pegRNAs and modular minimal budding modules boost prime and base editing in cells and restore gene function in retinal mouse models.
0:00Welcome to Base by Base, the papercast that brings genomics to you wherever you are. Thanks for listening, and don't forget to follow and rate us in your podcast app. You know, um, we spend so much time on this show just marveling at the sheer brilliance of genetic molecular scissors.
0:16Oh, absolutely. I mean, they're incredible. Right. We talk about technologies like CRISPR or base editors, prime editors, almost as if they're like microscopic magic wands. Like you just reach into the DNA, wave it around, and instantly cure a genetic disease.
0:29Yeah, that's definitely the pop science version. Exactly. But there is a massive real world dilemma. That frankly rarely makes the front page. We have a huge delivery problem. It truly is kind of the ultimate logistical nightmare of modern medicine because you have this highly precise, completely microscopic surgical kit, right?
0:50But how do you actually mail it to the exact right address inside the human body without, you know, triggering a massive immune crisis or causing irreversible damage? And not just get it there, but get it there without the package breaking in transit or getting lost entirely.
1:04Because right now, our current delivery methods are, well, they're kind of like using the world's most unreliable postal service. That is a very, very accurate way to frame it. Yeah, imagine you order this incredibly delicate life-saving machine, the delivery company puts it in their truck, but they permanently weld the package to the floor of the vehicle so you can never actually get it out and use it.
1:27Right, it's just stuck. Stuck. Or in another scenario, they rip the package open, successfully deliver the heavy machinery, but accidentally leave the fragile instruction manual out in the rain to just dissolve.
1:39Yeah, that's brutally accurate to the biochemical realities of our current delivery vectors. It's methy. It relies heavily on chance, and it frequently causes dangerous collateral damage. Which brings us to the absolute core of what we are exploring today.
1:54What really happens when we try to pack these complex molecular machines into cellular delivery vehicles, and how could redesigning the cargo hold entirely change the future of gene therapy? Because to answer those questions, we really have to look at a fundamental paradigm shift in how we engineer biological transport.
2:12I mean, we were talking about literally rewriting the rules of cellular logistics. Today, we celebrate the work of the research teams at Helmholtz, Munich, the technical University of Munich, and the University of California Irvine, who have advanced our understanding of safe and efficient gene editor delivery.
2:30Okay, let's unpack this. To really appreciate the brilliant solution these researchers came up with, we kind of need to understand the fatal flaws of the current heavyweights in the field, right? So let's start with the traditional viruses.
2:43Sure. So if you look at the current landscape of genome editing delivery, the traditional go to vehicles have basically always been viral vectors, specifically 80s, which are at no associated viruses and lengthy viruses.
2:54Right, the classic. The classics, yeah. And from a purely biological standpoint, they are incredibly good at infecting cells. I mean, 1000000s of years of evolution have made them, you know, perfect at breaking and entering, which makes them great at delivering a payload.
3:08But they have severe limitations for modern gene editing. First off, AAVs have a very limited cargo capacity. Think of them like a tiny sports car, basically. Exactly. A tiny sports car. Yeah. You simply cannot fit larger editors, like the massive prime editing systems, inside them easily.
3:27You literally have to split the editor into pieces and just hope it magically reassembles itself inside the cell, which is incredibly inefficient. Not to mention, if you're injecting large amounts of viruses into a patient, that can trigger a pretty severe immune response, right?
3:41Your body naturally recognizes it as an invader, but there is an even bigger, more insidious risk with these viruses, right? The persistence problem. Yes, this is um, this is the critical bottleneck for clinical safety.
3:53When AAVs or lendaviruses deliver a gene editor, they don't actually deliver the physical machine itself. Yet they don't? No, they deliver the genetic blueprint for the CRISPR enzyme. This forces the patient's own cell to manufacture the scissors from scratch.
4:08And the problem is, it keeps manufacturing them for a very, very long time. It persists. Oh, wow. And in gene editing, long-term expression is incredibly dangerous because it drastically increases the risk of off target genetic cuts.
4:21So it's sort of like leaving a highly caffeinated surgeon in the operating room indefinitely. Like if they stay in there for years, eventually they might just get bored and start operating on something they shouldn't.
4:32Precisely. The longer those DNA cutting tools are active in the cell, the higher the mathematical chance they eventually snip the wrong piece of DNA. And with lentiviruses, you have an additional, honestly terrifying risk known as insertional mutogenesis.
4:47Which means they insert their own DNA right? Exactly. Linaviruses actively integrate their own viral DNA directly into the host patient's genome. If that viral DNA happens to land directly inside, say, a tumor suppressor gene, you can disrupt the cell's natural defenses and potentially cause malignancies like cancer.
5:05Right. So relying on traditional viruses is just fraught with long-term risks. But what about the non-viral options? Because we hear a lot about LNPs, like lipid nanoparticles, especially after their massive success and the global rollout of the MRNA vaccines?
5:21They're just tiny bubbles of fat, so there's no viral DNA to worry about it all. L&Ps are excellent non-viral alternatives, absolutely. But they struggle heavily with cell type specificity. How so? Well, by default, anything you inject into the bloodstream tends to get swept up and filtered by the liver.
5:39It's just what the liver does. So if you wanted to target a very specific type of neuron deep in the brain, or a specific photoreceptor cell on the retina, LNTs require incredibly complex, very difficult to scale lipid formulation to trick the body's natural filtration systems.
5:55So they're kind of a blunt instrument? Very blunt. They're great for the liver, bad for almost everything else. Okay, so viruses are too persistent and risky, and LNPs are too blunt and nonspecific, which brings us to the biological Golbilox solution.
6:07Virus like particles or VLPs? They seem to bridge the gap perfectly. They really do. VLPs are just brilliant pieces of bioengineering because they look and act exactly like viruses on the outside. But they're empty.
6:20Exactly. They have the same outer shell, which allows them to efficiently target and enter specific cells, but they contain absolutely no viral genetic material on the inside. They are entirely hollow.
6:31And instead of delivering DNA that forces the cell to manufacture with a CRISPR enthyme. VLPs deliver the gene editor as a fully formed ribonuclear protein. Right. And because that ribonuclear protein or RNP already has the Kaz protein scissors and the RNA instruction manual physically bound together and ready to go, the target still doesn't actually have to build anything.
6:51Exactly. It just enters the cell, immediately navigates to the DNA, executes a specific genetic edit, and then the entire complex degrades safely within a few days. There is no persistent expression, there's no viral DNA integration.
7:04There's no long-term off target lingering. It just does the highly specific surgical job and then it vanishes. I love that. But here is where my confusion kicks in, right? If VLPs are this perfect, risk-free, Goldilocks solution.
7:18Why aren't we already using them in every hospital in the world? What is the specific mechanical flaw holding them back? That's the $10000000 question. And the bottleneck lies entirely. and how scientists have been attempting to pack that preassembled RNP into the hollow VLP shell.
7:34The cargo loading. Right. The standard legacy method in the field has always been to directly physically fuse the K's enzyme to the VLP's structural protein, which is called gag. You are literally tethering the heavy payload directly to the inner wall of the virus particle.
7:50Wait, if you permanently fuse the CRISPR enzyme to the structural wall of the delivery vehicle, how does it ever break free to navigate the target cells nucleus and actually edit the DNA? Ah. This race is an important question.
8:02And it highlights the exact fatal flaw of the legacy designs. Because it's a direct physical fusion, you are forced to rely on the target cell's internal chemistry to release the payload. You basically have to engineer complex protein linkers and just cross your fingers and hope that the cell uses a proteis enzyme to clumsily chalk the editor free once it's inside.
8:23That sounds super inefficient. It is highly inefficient. Furthermore, and this is the part that really ruins the entire process When you focus all your energy on packaging the massive Kaz enzyme by fusing it to the wall, it very often leaves its vital partner, the guide RNA, highly unstable, and physically unprotected.
8:41Ah, okay, so this goes directly back to that delivery truck analogy from the start. By fusing the cast protein to the gag structural protein, you are basically welding the driver to the car seat. And because you focus so much on forcing the driver into the vehicle, the fragile instruction manual, the guide RNA is just left loose and tumbling around in the back of the truck.
8:59Exactly. And it gets completely chewed up and destroyed by the cell's natural defense mechanisms before it can even be packaged. Right. And a cat's enzyme without its intact guide RNA is entirely useless.
9:12It is a pair of scissors operating completely blind. It literally doesn't know where to cut. Concisely. So how do the researchers at these institutions actually solve this? Because this doesn't sound like a simple biological tweak.
9:23This sounds like a mechanical engineering problem at the absolute microscopic level. It really was. It required a total paradigm shift in molecular packaging. So instead of anchoring the vehicle to the cast protein, the researchers created a completely new system called ENVLPE, which stands for engineered nucleocytosolic vehicles for loading of programmable editors.
9:45Okay, ENVLPE. Catchy. Yeah, and the fundamental breakthrough here was changing the anchor point. They decided to recruit the cargo into the vehicle by grabbing onto the guide RNA instead of the heavy cast protein.
9:56Wait, but physically, how is that even possible? I mean, RNA is incredibly fragile. You can't just bolt a heavy viral structural protein to a delicate strand of RNA without snapping it in half or ruining its ability to read DNA.
10:09How do they establish a grip? They used an incredibly elegant abtamer strategy. Yeah, and a paper is basically a short specific sequence of RNA that naturally folds into a unique 3D shape, acting almost like a biological handle.
10:21So the researchers tagged the guide to RNA with a specific RNA FTamer called PP7. Then they engineered the VLP's structural gag protein to include a matching receptor called a PCP domain. Oh, I see The PCP domain is geometrically designed to bind exclusively, and very tightly, to the 3D shape of the PP 7 app tamer.
10:40That is brilliant. So returning to our car analogy. Instead of welding the driver to the seat. You give the driver a highly customized steering wheel. That's the PP 7 tag. And the car itself, the VLP, is built with a steering column, the PCP domain, that only accepts that specific wheel.
10:54And since the Kaz enzyme naturally holds tightly onto its guide RNA anyway, the guide RNA clicks perfectly into the vehicle, dragging the Kaz enzyme along with it. This ensures that only fully assembled functional RMP complexes are loaded.
11:08That is the absolute beauty of RNA-based recruitment. If the case enzyme isn't properly holding the guide RNA, it just doesn't get packed. You only ever ship fully functional, ready to edit units. But, um, implementing this created a massive secondary logistical hurdle regarding where these components are physically located inside the manufacturing cell.
11:29Right, because the cell manufacturing these VLPs isn't just a big empty swimming pool, it has highly restricted compartments. The RMP complex, the K's protein, and the guide RNA assembles deep inside the cell's nucleus where all the RNA is transcribed.
11:43But the VLP delivery vehicle itself assembles way out at the cell membrane, out in the cytosol. So I'm stuck on how a protein forming at the outer boundary of the cell gets its hands on a microscopic strand of RNA locked deep inside the nucleus.
11:56This is where a mechanism called nucleositosolic shuttling comes in. The researchers essentially had to build a microscopic ferry system. They added very specific biological passport sequences to the structural gag protein.
12:08Specifically, they added a nuclear localization signal, or NLS, and a nuclear export signal, or NES. So the gag protein literally has clearance to cross the border. Exactly. The nucleus is heavily guarded by the nuclear poor complex, which acts just like a strict border checkpoint.
12:25The NLS acts as a VIP passport. It tells the cellular machinery to allow the gab protein to travel from the outer side of soul deep into the nucleus. Okay, so it gets in. Then what? Once inside, the gag protein uses that PCP domain to grab the fully assembled RMP V, it's a PP7 tag.
12:41Then, the NES acts at the exit visa. It tells the gag protein to shuttle back out of the nucleus, hauling the perfectly preassembled editor all the way to the outer cell membrane, where it's packaged into the budding VLP shell.
12:53It actively dips into the nucleus, grabs a cargo and hauls it out. That act of retrieval system is wild. But there has to be another layer of defense here, right? Because earlier you mentioned that guide RNAs, especially for the newer, more advanced editors, are incredibly fragile.
13:08Hauling them all the way across the cells sounds dangerous. It is extremely dangerous for the RNA. Especially if we're looking at prime editing, which is basically a molecular word processor that can rewrite DNA without causing massive double strand brakes.
13:23Prime editing requires a very specific, highly complex guide RNA called a hedge RNA. And these pej RNAs have a 3 prime extended region that just dangles loosely at the end. And having loose dangling RNA floating around inside a cell is basically ringing a dinner bell for cellular enzymes called exonucleuses, right?
13:41They act like microscopic Pac-Men that just chew up loose genetic material. Precisely. If that dangling end gets chewed up, the prime editor completely loses its ability to write new genetic code. So to protect the payload during this massive shuttling process, the researchers had to physically armor that fragile 3 prime end, they added distinct defensive features.
14:00First, a C4 motif. This acts as a molecular docking site for a highly protective protein called CC4. The CC4 protein physically clamps down on the end of the RNA, acting as a thick physical shield against those degrading enzymes.
14:16Ah, so it just blocks the Pac-Man from physically accessing the vulnerable tip. Exactly. And they didn't stop there. They also added an evo preQ1 pseudonot. Wait, a knot, like literally tying your shoelaces?
14:28Conceptually. Yeah, exactly like that. RNA is usually a loose single strand, but a pseudonot sequence forces that loose strand, chemically fold back on itself, and tie into a complex, incredibly bulky 3D tangle.
14:40So when the cell's natural Pac-Man enzymes try to chew up the RNA from the end. They literally cannot fit their microscopic mouths around the knot. It physically blocks degradation. Wow. So they didn't just change how the package is loaded.
14:51They completely encased the most delicate parts in molecular bubble wrap and titanium plating. They ensured that when the delivery truck arrives at the target cell, The instruction manual is perfectly intact, protected from the elements, and completely ready to be read.
15:04Here's where it gets really interesting, because the researchers didn't stop there. They optimize this entire system into an even better version they call ENVLPE plus Sari. What was the final upgrade? So the upgrade addressed a huge thermodynamic difficulty, specifically, how the gag proteins actually lock together to form the outer spherical shell of the VLP.
15:25Picture the cell membrane. It is a vast chaotic lipid sea. Right. These gag structural proteins are just floating around in this massive space, hoping they randomly bump into each other in the exact right orientation to spontaneously assemble into a perfect tight viral sphere is thermodynamically exhausting and highly inefficient.
15:44So the researchers added a GCN 4 coils coil domain to the gag proteins. How does a coiled coil domain solve the vastness of the cell membrane? It acts like heavily magnetized molecular velcro. It forces the gag proteins to homodimerize or tightly link up the moment they get near each other, the cell membrane.
16:01It overcomes that thermodynamic hurdle, snapping the pieces of the viral shell together much more effectively. And this structural boost led to staggering improvements in the actual data. Well, yeah, it's one thing to build a beautiful microscopic ferry system with molecular Velcro on paper, but biology is notoriously chaotic.
16:17When they actually tested this in human cells, what did they see? In strictly controlled in vitro tests, ENVLPE plus achieved up to 90% base editing efficiency at the B2M locus, in human-induced plurypotent stem cell derived cortical neurons.
16:3290%. And just to emphasize for a 2nd why that matters, stem cell derived cortical neurons are famously stubborn. They are notoriously difficult to edit without just outright killing the cell, getting 90% efficiency without relying on a dangerous, persistent virus is an incredible benchmark.
16:48It truly is. It drastically outperformed previous day of the art systems. When compared head to head with the previous standard vehicles in the field, like the V3B Prime editing VLPs of the V4 base editing VLPs, Eman VLPE plus showed significantly higher per particle editing efficiency across multiple different endogenous gene targets.
17:06But cell cultures in a Petri dish are one thing, you know? Biology inside a living organism involves immune systems, blood flow, and complex tissue architecture. Did this mechanism actually translate from the dish to living, breathing mammals?
17:20It did, and remarkably well. They moved the testing to Invivo mouse models for inherited retinal diseases, specifically the R 12 and Wordel 6 models. These mys feature severe genetic mutations that actively cause blindness.
17:34And the eye is historically an ideal testing zone for early gene therapies, right? It's relatively enclosed, immune privileged, and we have highly precise ways to measure if the therapy physically worked.
17:45Exactly. They injected the ENVLPE plus particles directly into the subretinal space of the mice. The VLPs successfully navigated to the retinal cells, delivered the highly protected base and prime editors, found the exact genetic mutations causing the disease, and cleanly reverted them back to the healthy DNA sequence.
18:03And we know it wasn't just, you know, a microscopic genetic parlor trick because they physically restored visual function in these mice. Wait, they could definitively prove the mice could see again. Yes.
18:13They proved it by measuring recordable ERG b-wave signals. An ERG, or electro retinogram measures the actual electrical activity of the eye in response to flashes of light. The untreated mice had flatlines.
18:27But the mice treated with ENVLPE plus showed clear, recordable electrical spikes, proving the retinal cells were functioning and transmitting visual data again. That is just amazing. They fundamentally cured genetic blindness in a living mammal using a completely non-viral, transiently acting delivery vehicle. That is a massive leap forward.
18:48So what does this all mean? When we zoom out from the mechanics of RNA up tamers and nucleocytosolic shuttling, Why does the ENVLPE system matter so much to the broader field of medicine? It fundamentally changes the game through the sheer power of modularity.
19:02Think about that direct fusion legacy method we discussed earlier, where the CRISPR enzyme is welded to the vehicle. If you wanted to switch your therapy from standard CRISPR Cast 9 to a base senator or to a prime editor, you basically had to redesign the entire delivery vehicle from scratch.
19:17Where you'd have to recalculate everything. Yeah, you had to recalculate the structural physics, engineer new linker proteins, and completely re-optimize the manufacturing process. took forever. But with ENVLPE plus R, because the vehicle only binds to that specific 3D RNA tag.
19:33Exactly. Because ENVLPE strictly recruits via the PP7 RNA tag, the system is universally modular. You can easily swap out a base editor for a prime editor, or use a standard cast 9 for straightforward genetic knockouts without having to redesign a single piece of the delivery vehicle itself.
19:52The vehicle stays exactly the same. You just swap out the payload as long as the new payload is holding that tag guide RNA. That dramatically speeds up the development pipeline for new therapies. You don't have to reinvent the truck every time you want to ship a different product.
20:04Let's talk about what this means for you, the listener, and the broader clinical applications. Imagine you or a loved one needs an advanced cellular therapy. Where do you see this having the biggest immediate impact?
20:16Oh, the immediate clinical applications are thrilling. X Vivo engineering is a major one. Think about car T cell therapy for cancer, where a patient's own immune cells are extracted, genetically engineered in a lab to aggressively fight cancer, and then infused back into the patient.
20:33Which is life-saving but risky. Right. Currently, that engineering process relies heavily on Lenaviruses, which carries that terrifying risk of insertional mutogenesis we discussed, with ENVLPE plus browwound, we could theoretically create those cancer fighting car T cells much more safely without exposing the patient to any risk of long-term viral DNA integration.
20:53And for targeting diseases directly inside the body, like in vivo treatments. For in Vivo, it opens the door to vastly safer treatments for localized diseases, like the genetic planus we just discussed, or specific muscular and neurological conditions.
21:07You can deliver a highly precise prime editor directly to the affected tissue, fix the mutation permanently, and then the entire editing machinery clears completely out of the body within days, drastically minimizing any long-term off target risks.
21:21If we connect this to the bigger picture, We are looking at a future where the safety profile of genetic medicine is no longer the primary bottleneck preventing widespread clinical use. Okay, but I have to play devil's advocate here.
21:34In biology, there is always a catch. Nature rarely gives us a completely free lunch. What are the limitations here? Where does ENVLPE plus still fall short? Well, you're right to ask, it is a massive leap in engineering, yes, but it isn't perfectly suited for everything.
21:48The very thing that makes VLPs so incredibly safe, they're transient, short-lived nature means they might not be ideal if the required genetic edit isn't permanent in actively dividing cells. Ah, see. Yeah, if you have a disease that requires a continuous ongoing therapeutic presence, a transient RNP delivery won't cut it.
22:06Furthermore, while the researchers did test this system for CRISPR activation, which is turning a specific gene on rather than cutting it, and for homology directed repair, which is inserting large sequences of completely new DNA, those were strictly proof of concept experiments.
22:22They aren't fully optimized for the clinic yet. So it is an absolute powerhouse for making permanent, highly precise single point edits, but maybe less suited for continuous lifelong gene regulation. What is the next big frontier for this technology?
22:37How do we make it even better? The absolute next frontier will be pseudotyping. This means heavily engineering the outer glycoproteins of the VLP, the molecular keys on the surface of the shell, so that the vehicle can actively target specific organs with pinpoint accuracy.
22:52Oh wow. Yeah. Imagine you have a genetic condition in your liver, but a different treatment might harm your heart. With advanced suitor typing, scientists could program a VLP, so that when injected into your bloodstream, it completely ignores your lungs, bypasses your heart, and delivers its payload exclusively to the hepatites in your liver, or perhaps engineered to cleanly cross the blood brain barrier to edit specific cortical neurons.
23:17It's turning the delivery truck into a highly intelligent homing missile. We've covered incredible brown today, diving deep into the microscopic physics of gene delivery. How would you distill all of this complex engineering down for us?
23:30If you take away just one central insight from this research, let it be this. ENVLPE plus fundamentally changes how we package gene editors by utilizing active nucleocytosolic shuttling and RNA-based recruitment.
23:43This elegant system ensures that only fully assembled, heavily protected editing machines are delivered to target cells, dramatically increasing both the efficiency and the absolute safety of future gene therapies.
23:54What does this mean for the future of genetic medicine when the delivery truck becomes just as programmable as the curate carries? This episode was based on an open access article under the CCBY 4.0 license.
24:05You can find a direct link to the paper and the license in our episode description. If you enjoyed this, follow or subscribe in your podcast app and leave a 5 star rating. If you'd like to support our work, use the donation link in the description.
24:18Now stay with us for an original track created especially for this episode and inspired by the article you've just heard about. Thanks for listening and join us next time as we explore more science base by base.
